Search This Blog

Wednesday, April 8, 2020

Mylan to donate 10M doses of malaria drug as production ramps up

Mylan N.V. (MYL +5.7%) announces that its production of malaria med hydroxychloroquine sulfate at its Morgantown, WV site has advanced ahead of schedule and has enabled the supply of additional product earlier than expected for COVID-19 patients.
It is donating 10M doses to the U.S. Department of Health and Human Services for possible use in clinical studies or under emergency use authorization. It is also donating product to the World Health Organization (WHO).
Shipments to wholesalers are underway.
https://seekingalpha.com/news/3559464-mylan-to-donate-10m-doses-of-malaria-drug-production-ramps-up

Anika Therapeutics beefs up liquidity amid COVID-19 disruptions

Aimed at strengthening its financial position during the uncertainties associated with the current pandemic, Anika Therapeutics (NASDAQ:ANIK) is drawing $50M from its existing credit facility, beefing up its total liquidity to ~$140M.
It potentially has another $50M per an accordion feature and it is exploring additional funding sources since it wants to maintain its business and staff during COVID-19. It has implemented a number of short-term expense controls as well.
Shares down 3% after hours.
https://seekingalpha.com/news/3559480-anika-therapeutics-beefs-up-liquidity-amid-covidminus-19-disruptions

Organogenesis has prelim 1Q20 revenue, withdraws FY20 revenue guidance

Organogenesis (ORGO +3.9%) announces it has withdrawn the previously announced revenue guidance for FY20, due to the impact of COVID-19.
Company reported preliminary 1Q20 results, expects Net revenue between $61M and $61.6M, up 7% to 8% from last year, vs. consensus of $60.64M; and net revenue from PuraPly products between $32.1M and $32.5M, up by 26% to28% from last year.
Company to report 1Q20 financial results after the market closes on May 11, 2020.
https://seekingalpha.com/news/3559494-organogenesis-reports-preliminary-1q20-revenue-and-withdraws-fy20-revenue-guidance

Vanda Pharma up 12% after hours on COVID-19 drug development plan

Vanda Pharmaceuticals (NASDAQ:VNDA) will collaborate with the University of Illinois at Chicago to investigate small molecules for the potential treatment of COVID-19.
The partnership will include the use of a high-throughput screening assay to identify candidates that may prevent cathepsin-L cleavage of SARS-CoV-2 glycoproteins that are required for viral processing in the host cell.
The company says it is also exploring drugs that may block the virus from entering the cell at an entry point called the angiotensin converting enzyme 2 receptor and drugs that inhibit the transmembrane protease serine 2 precursor.
The program includes the initiation of a study, ODYSSEY, evaluating tradipitant in hospitalized severely ill patients with COVID-19 pneumonia.
Shares up 12% after hours.
https://seekingalpha.com/news/3559497-vanda-pharma-up-12-after-hours-on-covidminus-19-drug-development-plan

Genfit reports FY results

Genfit (NASDAQ:GNFT): FY GAAP EPS of -€1.76.
Revenue of €40.96M (+446.9% Y/Y)
https://seekingalpha.com/news/3559500-genfit-reports-fy-results

Guidance for Licensed Pharmacists, COVID-19 Testing

On January 31, 2020, the Secretary of Health and Human Services declared that the 2019 novel coronavirus (COVID-19) is a public-health emergency for the United States. The United States Department of Health and Human Services (HHS) is the lead agency for the federal government’s response to the COVID-19 pandemic.
A key component of that response is rapidly expanding COVID-19 testing across America. Within HHS, the Office of the Assistant Secretary for Health leads federal efforts to support that expansion.
Pharmacists, in partnership with other healthcare providers, are well positioned to aid COVID-19 testing expansion. Pharmacists are trusted healthcare professionals with established relationships with their patients. The vast majority of Americans live close to a retail or independent community-based pharmacy. That proximity reduces travel to testing locations, which is an important mitigation measure. Pharmacists also have strong relationships with medical providers and hospitals to appropriately refer patients when necessary.
Therefore, as an Authority Having Jurisdiction under the Secretary’s March 10, 2020 declaration under the Public Readiness and Emergency Preparedness Act (PREP Act), OASH issues this guidance authorizing licensed pharmacists to order and administer COVID-19 tests, including serology tests, including serology tests, that the Food and Drug Administration (FDA) has authorized. See 85 Fed. Reg. 15,198, 15,202 (March 17, 2020); see also Pub. L. No. 109-148, Public Health Service Act § 319F-3, 42 U.S.C. § 247d-6d and 42 U.S.C. § 247d-6e.1 By doing so, such pharmacists will qualify as “covered persons” under the PREP Act. And they may receive immunity under the PREP Act with respect to all claims for loss caused by, arising out of, relating to, or resulting from, the administration or use of FDA-authorized COVID-19 tests. 42 U.S.C. § 247d-6d(a)(1).

Amarin to announce preliminary Q1 results April 13

Amarin (NASDAQ:AMRN) will host a conference call on Monday, April 13, at 4:30 pm ET to provide preliminary Q1 results and to update on its operations, including its planned appeal of the adverse patent related to Vascepa (icosapent ethyl).
Current consensus is a loss/share of ($0.09) on revenue of $129M.
Shares down 1% after hours.
https://seekingalpha.com/news/3559475-amarin-to-announce-preliminary-q1-results-april-13